Transplacental Flecainide Therapy for Fetal Supraventricular Tachycardia in a Twin Pregnancy

Authors

  • Andrew Edwards MRACOG,,

    Corresponding author
    1. Department of Obstetrics and Gynaecology, Canberra Clinical School, University of Sydney, The Canberra Hospital, Canberra
    Search for more papers by this author
    • 1

      Senior Registrar in Obstetrics and Gynaecology.

  • Michael J. Peek BSc(Med)(Hons), PhD, MRCOG, FRACOG, DDU, CMFM,

    1. Department of Obstetrics and Gynaecology, Canberra Clinical School, University of Sydney, The Canberra Hospital, Canberra
    Search for more papers by this author
    • 2

      Senior Lecturer, Department of Obstetrics and Gynaecology.

  • Jan Curren Grad Dip Ultrasound

    1. Department of Obstetrics and Gynaecology, Canberra Clinical School, University of Sydney, The Canberra Hospital, Canberra
    Search for more papers by this author
    • 3

      Senior Sonographer, Fetal Medicine Unit.


5 Obstetrics and Gynaecology, Fetal Medicine Unit, The Canberra Hospital, PO Box 11, Woden, ACT, 2606.

Abstract

Summary: We present the case of a twin pregnancy in which 1 fetus developed hydrops secondary to supraventricular tachycardia at 30 weeks' gestation. Transplacental flecainide administration successfully treated the condition without evidence of maternal or fetal side-effects. The case raises ethical and possibly legal issues that present when 1 fetus in a twin pregnancy develops a condition the management of which could cause complications to the other twin and/or the mother.

Ancillary